SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. – YMAB – Y-mAbs Therapeutics (NASDAQ:YMAB) – Press Release
[ad_1]
NEW YORK, Oct. 10, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) YMAB. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Y-mAbs and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On October 5, 2020, post-market, Y-mAbs issued a press release disclosing receipt of “a Refusal to File letter from the U.S. Food and Drug Administration (‘FDA’) regarding the Biologics License Application (‘BLA’) for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma, which was submitted in August 2020.” Y-mAbs advised investors that “[u]pon preliminary review, the FDA determined that certain parts of the Chemistry, Manufacturing and Control (‘CMC’) module and the Clinical module of the BLA require further detail.”
On this news, y-mAbs’s stock price fell $3.57 per share, or 8.56%, to close at $38.13 per share on October 6, 2020.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-y-mabs-therapeutics-inc—ymab-301645255.html
SOURCE Pomerantz LLP
[ad_2]
Source link
